Chen, S., Li, T., Ma, W., Lu, T., Long, S., Toomey, K. A., . . . Ogilhara, N. (2023). 632 A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas. BMJ Publishing Group.
Chicago Style (17th ed.) CitationChen, Shuai, et al. 632 A Phase 1/2 Open Label Study of LabVax 3(22)-23 and Adjuvant GM-CSF Alone or in Combination with Pembrolizumab in Subjects with Labyrinthin-positive Adenocarcinomas. BMJ Publishing Group, 2023.
MLA (9th ed.) CitationChen, Shuai, et al. 632 A Phase 1/2 Open Label Study of LabVax 3(22)-23 and Adjuvant GM-CSF Alone or in Combination with Pembrolizumab in Subjects with Labyrinthin-positive Adenocarcinomas. BMJ Publishing Group, 2023.
Warning: These citations may not always be 100% accurate.